Cell No. : Cell Name
RCB1900 : Lu99
update : 2021/05/20
|
| Comment | Lung giant cell carcinoma cell line derived from human. TKG0495 (Deposited from Tohoku Univ.). |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Obinata, Masuo
|
| Originator |
Hirohashi, S. and Shimosatao, Y.
|
| Year of deposit |
2004
|
| Original cell |
TKG0495
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Gender |
Male
|
| Age at sampling |
63 years
|
| Tissue |
lung
|
| Disease name |
Giant cell carcinoma
|
| Classification |
cancer
|
| History |
Cell Resource Center for Biomedical Research, Tohoku University（TKG0495）
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_3015
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Medium and additives |
|
RPMI1640 + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% trypsin
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
53-58(50) : 53(5),54(9),55(12),56(12),57(6),58(6)
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
1
|
| User's Publication |
13
|
| User's Publication |
|
13304
Colombo M, Marabese M, Vargiu G, Broggini M, Caiola E.
Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations.
Front Oncol
2020
PubMed ID: 33194590
|
|
13773
Saigusa D, Motoike IN, Saito S, Zorzi M, Aoki Y, Kitamura H, Suzuki M, Katsuoka F, Ishii H, Kinoshita K, Motohashi H, Yamamoto M.
Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites
Cancer Sci
2020
111(2):667-678
PubMed ID: 31828882
|
|
13841
Eguchi R, Wakabayashi I.
HDGF enhances VEGF‑dependent angiogenesis and FGF‑2 is a VEGF‑independent angiogenic factor in non‑small cell lung cancer
Oncol Rep
2020
44(1):14-28
PubMed ID: 32319650
|
|
13925
Iezzi A, Caiola E, Colombo M, Marabese M, Broggini M.
Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell lines
Am J Cancer Res
2020
10(12):4488-4497
PubMed ID: 33415013
|
|
11496
Miyake N, Chikumi H, Yamaguchi K, Takata M, Takata M, Okada K, Kitaura T, Nakamoto M, Yamasaki A.
Effect of Cetuximab and EGFR Small Interfering RNA Combination Treatment in NSCLC Cell Lines with Wild Type EGFR and Use of KRAS as a Possible Biomarker for Treatment Responsiveness.
Yonago Acta Med
2019
PubMed ID: 30962749
|
|
4280
Rawangkan A, Wongsirisin P, Namiki K, Iida K, Kobayashi Y, Shimizu Y, Fujiki H, Suganuma M.
Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth.
Molecules
2018
PubMed ID: 30126206
|
|
7006
Iida K, Sakai R, Yokoyama S, Kobayashi N, Togo S, Yoshikawa HY, Rawangkan A, Namiki K, Suganuma M.
Cell softening in malignant progression of human lung cancer cells by activation of receptor tyrosine kinase AXL.
Sci Rep
2017
7:17770
PubMed ID: 29259259
|
|
14222
Horie M, Kaczkowski B, Ohshima M, Matsuzaki H, Noguchi S, Mikami Y, Lizio M, Itoh M, Kawaji H, Lassmann T, Carninci P, Hayashizaki Y, Forrest ARR, Takai D, Yamaguchi Y, Micke P, Saito A, Nagase T.
Integrative CAGE and DNA Methylation Profiling Identify Epigenetically Regulated Genes in NSCLC
Mol Cancer Res
2017
15(10):1354-1365
PubMed ID: 28698358
|
|
14130
Marjon K, Cameron MJ, Quang P, Clasquin MF, Mandley E, Kunii K, McVay M, Choe S, Kernytsky A, Gross S, Konteatis Z, Murtie J, Blake ML, Travins J, Dorsch M, Biller SA, Marks KM.
MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis
Cell Rep
2016
15(3):574-587
PubMed ID: 27068473
|
|
7462
Tomita T, Ieguchi K, Sawamura T, Maru Y.
Human serum amyloid A3 (SAA3) protein, expressed as a fusion protein with SAA2, binds the oxidized low density lipoprotein receptor.
PLoS ONE
2015
10:e0118835
PubMed ID: 25738827
|
|
15129
Kusakabe K, Ide N, Daigo Y, Itoh T, Yamamoto T, Hashizume H, Nozu K, Yoshida H, Tadano G, Tagashira S, Higashino K, Okano Y, Sato Y, Inoue M, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Kido Y, Sakamoto S, Ando S, Maeda M, Higaki M, Baba Y, Nakamura Y.
Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity
J Med Chem
2015
58(4):1760-75
PubMed ID: 25625617
|
|
5833
Sato M, Muguruma N, Nakagawa T, Okamoto K, Kimura T, Kitamura S, Yano H, Sannomiya K, Goji T, Miyamoto H, Okahisa T, Mikasa H, Wada S, Iwata M, Takayama T.
High antitumor activity of pladienolide B and its derivative in gastric cancer.
Cancer Sci
2014
105(1):110-6
PubMed ID: 24635824
|
|
15715
Menju T, Hashimoto S, Hashimoto A, Otsuka Y, Handa H, Ogawa E, Toda Y, Wada H, Date H, Sabe H.
Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma
PLoS One
2011
6(9):e25301
PubMed ID: 21966491
|
Back
Top
CELL BANK Website